Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong

Rhea-AI Summary

Avalon GloboCare (NASDAQ: ALBT) has secured a new patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. The patent (No. HK40074322), co-developed with Arbele Limited, provides 20-year protection effective from February 21, 2020.

The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction system aimed at enhancing immune responses at tumor sites. This patent complements Avalon's existing protections in the United States and other PCT jurisdictions, strengthening their position in cell-based immunotherapy development.

Positive

• Secured 20-year patent protection in Hong Kong through 2040
• Technology targets multiple antigens (CD19 and CD22) to reduce treatment resistance
• Complements existing patent protections in US and other jurisdictions
• Strategic partnership with Hong Kong-based Arbele Limited

Negative

• None.

Insights

Biotechnology Patent Expert

Avalon secured 20-year Hong Kong patent protection for its dual-target CAR-T/NK cell technology, strengthening its global IP position through 2040.

Avalon GloboCare's new Hong Kong patent represents a strategic expansion of their intellectual property portfolio in cell-based immunotherapy. The patent (No. HK40074322) specifically protects their innovative bispecific anti-CD19xCD22 CAR design and localized cytokine induction technology.

The bispecific approach targeting both CD19 and CD22 antigens addresses a critical challenge in CAR therapies - antigen escape. When cancer cells lose expression of a targeted antigen (like CD19), they can evade single-target CAR-T therapies. By simultaneously targeting two antigens, Avalon's technology potentially reduces this treatment failure mechanism in blood cancers.

Their localized cytokine induction approach represents another significant innovation. By restricting cytokine activity to tumor sites, this technology aims to enhance CAR cell performance while potentially reducing systemic toxicity issues like cytokine release syndrome that plague current CAR therapies.

This patent, co-owned with Hong Kong-based Arbele Limited, complements Avalon's existing protections in the US and other PCT jurisdictions. The 20-year protection period (effective from February 2020) provides Avalon long-term market exclusivity through 2040 in the Hong Kong region, creating potential licensing opportunities and strengthening their competitive position in the rapidly evolving cell therapy landscape.

FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department (HKIPD) for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology.

Granted based on a Chinese patent (ZL202080015205.0) and issued as Patent No. HK40074322, the Certificate of Invention represents a significant milestone in Avalon’s global intellectual property strategy. The 20-year patent term, effective February 21, 2020, provides long-term protection for the Company’s proprietary CAR-T and CAR-Natural Killer (NK) cell technology innovations in the Hong Kong Special Administrative Region.

Co-developed and co-owned with Avalon’s strategic partner Arbele Limited, based in Hong Kong, this patent advances Avalon’s positioning in chimeric antigen receptor (CAR)-based cell therapies. It complements the Company’s existing patent protections in the United States and other jurisdictions under the Patent Cooperation Treaty (PCT).

The patented technology is designed to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells including:

• Bispecific Anti-CD19xCD22 CAR Design: Targets both CD19 and CD22 antigens expected to reduce the risk of tumor escape via antigen loss, a common challenge in hematologic malignancies.
  
• Localized Cytokine Induction: Intended to activate immune responses specifically at tumor sites, expected to improve CAR cell proliferation, cytotoxicity, and persistence while also attempting to stimulate the patient’s own immune system.
  

“Securing this patent in Hong Kong marks an important expansion of our global intellectual property portfolio and reinforces our competitive positioning in the rapidly advancing field of cell-based immunotherapy,” said David Jin, M.D., Ph.D., Avalon’s CEO. “With 20 years of patent protection for our CAR-T and CAR-NK cell technology now secured in Hong Kong through 2040, this achievement represents a strategic step in strengthening our intellectual property portfolio.”

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device, which is owned and manufactured by Qi Diagnostics Limited, and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir^TM is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate. For more information about Avalon, please visit www.avalon-globocare.com.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).

Additional Information About the Proposed Merger for Investors and Shareholders

This communication relates to the proposed merger (the “proposed Merger”) of Avalon and YOOV Group Holding Limited (“YOOV”). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4, as amended, that contains a preliminary prospectus and preliminary proxy statement of Avalon (the “proxy statement/prospectus”). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon’s stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.

Participants in the Solicitation

Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon’s directors and executive officers is available in Avalon’s Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com

FAQ

What patent did Avalon GloboCare (ALBT) receive in Hong Kong?

Avalon received Patent No. HK40074322 for their proprietary CAR-T and CAR-Natural Killer (NK) cell technology, providing protection through 2040.

What are the key features of Avalon's patented CAR-T technology?

The technology features a bispecific Anti-CD19xCD22 CAR design targeting both antigens to reduce tumor escape risk, and a localized cytokine induction system for enhanced immune responses.

Who owns the new Hong Kong CAR-T patent with Avalon GloboCare?

The patent is co-owned and co-developed with Arbele Limited, Avalon's strategic partner based in Hong Kong.

How long is Avalon's new CAR-T patent valid in Hong Kong?

The patent provides 20-year protection, effective from February 21, 2020, extending through 2040.

What territories are covered by Avalon's CAR-T patent protection?

Avalon has patent protection in Hong Kong, the United States, and other jurisdictions under the Patent Cooperation Treaty (PCT).